dkd (CANDOR Bioscience)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

CANDOR Bioscience dkd
Dkd, supplied by CANDOR Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/image+processing+software+gnu+image+manipulation+program+version+2%2E8%2E4/dkd/pmc10727041-8-3-1
Average 90 stars, based on 1 article reviews

dkd - by Bioz Stars, 2026-11

90/100 stars

Images

other:

Article Title: Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison.
Article Snippet: All Cox regressions used the comparator as the reference group (i.e., DKd [CANDOR], DVd [CASTOR]).

Article Title: Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison
Article Snippet: DPd (MM-014 Cohort B) vs. DKd (CANDOR) , DPd – Naive , 80 , 1.00 (0.69, 1.45) , 0.996 , 0.605 , 56.64 (38.42, NE) , 0.89 (0.83, 0.97) , 0.71 (0.61, 0.82) , 0.62 (0.52, 0.75) , 0.57 (0.46, 0.70).

Article Title: Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Article Snippet: 32 Among patients in CANDOR who had received 1 prior line of therapy, ORR and ≥CR rates were higher in the D-Kd group than in the Kd group, regardless of relapse status (with early relapse defined as relapse <18 months after the first line of therapy), and PFS results also favored the D-Kd group, regardless of relapse status.

Article Title: A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.
Article Snippet: The newest combinations of D-KD and I-KD are likely to become the new standard of care for this setting of patients, with the unprecedented PFS of 28.1 months reported in the CANDOR trial [26] and the significant benefit of the triplet regimen in the IKEMA trial as well [27].

Article Title: Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real-world clinical setting.
Article Snippet: To the editor Gain/amplification of 1q21 (1 q21þ) are chromosomal abnormalities frequently observed in patients with multiple myeloma (MM), present in approximately 30% of patients at initial diagnosis, and increasing in frequency with disease progression.. The 1q21þ abnormalities are poor prognostic chromosomal abnormalities, with a weight of 0.5 points assigned to 1q21þ in the R2‐ISS score.. Daratumumab is an anti‐CD38 monoclonal antibody effective in patients with newly diagnosed (ND) or relapsed/refractory (RR) MM, with good responses achieved even in patients with high‐risk chromosomal abnormalities (HRCAs).

Control:

Article Title: Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
Article Snippet: Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA US Myeloma Innovations Research Collaborative (USMIRC), Westwood, Kansas, USA Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, Kansas, USA Division of Hematology/Oncology, Medical University of South Carolina, Charleston, South Carolina, USA Medical University of South Carolina School of Medicine, Charleston, South Carolina, USA University of Kansas School of Medicine, Kansas City, Kansas, USA Division of Hematology/Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Comparison:

Drug discovery:

Article Title: Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
Article Snippet: .. These include the ARROW study , which compared the administration regimens of CFZ at 70 mg/m 2 once a week and 27 mg/m 2 twice a week; the IKEMA study , which evaluated the differences in therapeutic efficacy between the Isa-Kd (Isa monoclonal antibody combined with CFZ and dexamethasone) and Kd regimens; the CANDOR study , which compared the DKd and Kd regimens. ..

Review